An official website of the United States government
Home
Name
M-BAM
Alternate names
None
Primary Site
None
Histology
None
Radiation
None
Remarks
None
Drugs for M-BAM
Name
Alternate Names
Campath
Abbreviations
None
Category
Biologic therapy (BRM, immunotherapy)
Subcategory
Targeted therapy
NSC Number
715969
Primary Site
Leukemia
lymphoma
Histology
None
Remarks
JANUARY 2013 IMPORTANT UPDATE: This drug has changed categories. A comprehensive review has been completed and in keeping with the FDA, this drug is to be coded as a Biologic therapy/Immunotherapy agent. Effective with diagnosis date January 1, 2013 forward, code alemtuzumab as BRM/Immunotherapy.For cases diagnosed prior to January 1, 2013 continue coding this drug as chemotherapy.
FDA approved use on chronic lymphocytic leukemia.
FDA approved use on chronic lymphocytic leukemia.
Coding
This drug should be coded
Name
Alternate Names
None
Abbreviations
None
Category
Radiation
Subcategory
Radioisotope
NSC Number
None
Primary Site
Liver
Histology
None
Remarks
Yttrium 90 imbedded in glass microspheres embolized in liver near the tumor. MDS Nordion
Coding
This drug should be coded
Name
Alternate Names
Asta B 518
B-518
Clafen Claphene
Cyclophosphamid
Cyclophosphan
Cyclophosphane
Cytophosphan
Cytoxan
Endoxan
Endoxana
Enduxan
Genoxal
Neosar
Procytox
Sendoxan
Tymtram
WR-138719
Abbreviations
CP
CPM
CTX
CTY
CYC
Cyclo
CYT
CYTOX
CYTX
Category
Chemotherapy
Subcategory
Alkylating agent
NSC Number
026271
26271
Primary Site
Histology
None
Remarks
An effective antineoplastic agent and is used for a variety of cancers. FDA approved uses on breast cancer, ovarian carcinoma, leukemia, lymphomas, multiple myeloma, neuroblastma, retinoblastoma, soft tissue sarcoma, Wilm's tumor. Alkylating agent
Coding
This drug should be coded
